4.5 Review

Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization

Journal

STEM CELLS INTERNATIONAL
Volume 2018, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2018/4083921

Keywords

-

Funding

  1. FAPESP [2012/23228-4]
  2. CTC (Center for Cell-Based Therapy) [FAPESP 2013/08135-2]
  3. National Institute of Science and Technology in Stem Cell and Cell Therapy [CNPq 573754-2008-0, FAPESP 2008/578773]

Ask authors/readers for more resources

Over the last decades, mesenchymal stromal cells (MSC) have been the focus of intense research by academia and industry due to their unique features. MSC can be easily isolated and expanded through in vitro culture by taking full advantage of their self-renewing capacity. In addition, MSC exert immunomodulatory effects and can be differentiated into various lineages, which makes them highly attractive for clinical applications in cell-based therapies. In this review, we attempt to provide a brief historical overview of MSC discovery, characterization, and the first clinical studies conducted. The current MSC manufacturing platforms are reviewed with special attention regarding the use of bioreactors for the production of GMP-compliant clinically relevant cell numbers. The first commercial MSC-based products are also addressed, as well as the remaining challenges to the widespread use of MSC-derived products.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available